Cargando…

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

Treatment of disseminated tuberculosis in children ≤ 6 years has not been optimized. The pyrazinamide-containing combination regimen used to treat disseminated tuberculosis in babies and toddlers was extrapolated from adult pulmonary tuberculosis. Due to hepatotoxicity worries, there are no dose–res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Srivastava, Shashikant, Pasipanodya, Jotam G., Ramachandran, Geetha, Deshpande, Devyani, Shuford, Stephen, Crosswell, Howland E., Cirrincione, Kayle N., Sherman, Carleton M., Swaminathan, Soumya, Gumbo, Tawanda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856747/ https://www.ncbi.nlm.nih.gov/pubmed/27211555 http://dx.doi.org/10.1016/j.ebiom.2016.02.040

Ejemplares similares

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo
por: Deshpande, Devyani, et al.
Publicado: (2016)

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way
por: Deshpande, Devyani, et al.
Publicado: (2016)

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests
por: Swaminathan, Soumya, et al.
Publicado: (2016)

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps
por: Deshpande, Devyani, et al.
Publicado: (2016)

Amikacin Optimal Exposure Targets in the Hollow-Fiber System Model of Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Minocycline intra-bacterial pharmacokinetic hysteresis as a basis for pharmacologic memory and a backbone for once-a-week pan-tuberculosis therapy
por: Deshpande, Devyani, et al.
Publicado: (2022)

A Combination Regimen Design Program Based on Pharmacodynamic Target Setting for Childhood Tuberculosis: Design Rules for the Playground
por: Srivastava, Shashikant, et al.
Publicado: (2016)

Antibacterial and Sterilizing Effect of Benzylpenicillin in Tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2018)

Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Hollow-fibre system model of tuberculosis reproducibility and performance specifications for best practice in drug and combination therapy development
por: Gumbo, Tawanda, et al.
Publicado: (2023)

Linezolid Dose That Maximizes Sterilizing Effect While Minimizing Toxicity and Resistance Emergence for Tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2017)

Evaluation of Ceftriaxone Plus Avibactam in an Intracellular Hollow Fiber Model of Tuberculosis: Implications for the Treatment of Disseminated and Meningeal Tuberculosis in Children
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Systematic Review and Meta-analyses of the Effect of Chemotherapy on Pulmonary Mycobacterium abscessus Outcomes and Disease Recurrence
por: Pasipanodya, Jotam G., et al.
Publicado: (2017)

Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
por: Gumbo, Tawanda, et al.
Publicado: (2021)

A Meta-Analysis of Self-Administered vs Directly Observed Therapy Effect on Microbiologic Failure, Relapse, and Acquired Drug Resistance in Tuberculosis Patients
por: Pasipanodya, Jotam G., et al.
Publicado: (2013)

1659. Pharmacokinetics/pharmacodynamics of the Novel Gyrase Inhibitor SPR719/SPR720 and Clinical Dose Selection to Treat Pulmonary Mycobacterium avium-complex Disease
por: Deshpande, Devyani, et al.
Publicado: (2020)

Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii
por: Srivastava, Shashikant, et al.
Publicado: (2021)

Omadacycline efficacy in the hollow fibre system model of pulmonary Mycobacterium avium complex and potency at clinically attainable doses
por: Chapagain, Moti, et al.
Publicado: (2022)

Bacterial load slopes represent biomarkers of tuberculosis therapy success, failure, and relapse
por: Magombedze, Gesham, et al.
Publicado: (2021)

Ceftazidime-avibactam has potent sterilizing activity against highly drug-resistant tuberculosis
por: Deshpande, Devyani, et al.
Publicado: (2017)

1697. Dose-response Studies of the Novel Bacterial Leucyl-tRNA Synthetase Inhibitor, Epetraborole, in the Intracellular Hollow Fiber System Model of Mycobacterium avium complex Lung Disease
por: Chapagain, Moti, et al.
Publicado: (2022)

Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments
por: Liu, Yongge, et al.
Publicado: (2023)

Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics
por: Srivastava, Shashikant, et al.
Publicado: (2020)

Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases
por: Deshpande, Devyani, et al.
Publicado: (2016)

Therapy duration and long-term outcomes in extra-pulmonary tuberculosis
por: Pusch, Tobias, et al.
Publicado: (2014)

Artificial Intelligence and Amikacin Exposures Predictive of Outcomes in Multidrug-Resistant Tuberculosis Patients
por: Modongo, Chawangwa, et al.
Publicado: (2016)

Amikacin Concentrations Predictive of Ototoxicity in Multidrug-Resistant Tuberculosis Patients
por: Modongo, Chawangwa, et al.
Publicado: (2015)

Pyrazinamide clearance is impaired among HIV/tuberculosis patients with high levels of systemic immune activation
por: Vinnard, Christopher, et al.
Publicado: (2017)

Redox Imbalance and Oxidative DNA Damage During Isoniazid Treatment of HIV-Associated Tuberculosis: A Clinical and Translational Pharmacokinetic Study
por: Zentner, Isaac, et al.
Publicado: (2020)

The pyrazinamide susceptibility breakpoint above which combination therapy fails
por: Gumbo, Tawanda, et al.
Publicado: (2014)

Tuberculous Pericarditis is Multibacillary and Bacterial Burden Drives High Mortality
por: Pasipanodya, Jotam G., et al.
Publicado: (2015)

Comparison of Rifamycins for Efficacy Against Mycobacterium avium Complex and Resistance Emergence in the Hollow Fiber Model System
por: Boorgula, Gunavanthi D., et al.
Publicado: (2021)

Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
por: Srivastava, Shashikant, et al.
Publicado: (2022)

The Non-Linear Child: Ontogeny, Isoniazid Concentration, and NAT2 Genotype Modulate Enzyme Reaction Kinetics and Metabolism
por: Rogers, Zoe, et al.
Publicado: (2016)

Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis
por: Rockwood, Neesha, et al.
Publicado: (2017)

Comment on “Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections”
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Safety and tolerability of long-term use of omadacycline in the treatment of Mycobacterium abscessus infections
por: Srivastava, Shashikant, et al.
Publicado: (2023)

Comparative Effectiveness of Methotrexate versus Methylprednisolone in Treatment Naïve Pulmonary Sarcoidosis Patients
por: Pasipanodya, Jotam G.
Publicado: (2021)

Poor Penetration of Antibiotics Into Pericardium in Pericardial Tuberculosis
por: Shenje, Justin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_qmo73vq05dsdt9063fnvlu6r4q